Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Mind Medicine (MindMed) Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "PRODUCT CANDIDATE INDICATION PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 REGISTRATION"
08/14/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT dated as of August 11, 2023 is entered into among MIND medicine INC., a corporation incorporated under the laws of the Province of British Columbia , and each other Person party hereto as a borrower set forth on Schedule 1 hereto from time to time , and each other Person party hereto or party to any other Loan Document as a guarantor from time to time , K2 HEALTHVENTURES LLC, as a lender, and the other lenders from time to time party hereto , K2 HEALTHVENTURES LLC, as administrative agent for Lenders and collateral agent for the Lenders under the Canadian Security Documents , and ANKURA TRUST COMPANY, LLC, as collateral trustee for Lenders . AGREEMENT Borrower Representative, each Loan Party from time to time party hereto, Admini..."
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "MindMed Reports Second Quarter 2023 Financial Results and Business Highlights – Topline readout of MM-120 in GAD expected in Q4 2023 with enrollment to be concluded in Q3 2023 – – Topline readout of MM-120 in ADHD anticipated in Q4 2023 / Q1 2024 – – MM-402 in ASD on track for Phase 1 clinical trial initiation in Q4 2023 – – Entered into exclusive license agreement with Catalent for MM-120 Zydis® orally disintegrating tablet formulation for advancement into pivotal clinical trials – – Cash and cash equivalents of $116.9 million at June 30, 2023 – – Company to host conference call today at 4:30 PM ET –"
07/25/2023 8-K/A Quarterly results
06/16/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/16/2023 8-K Other Events  Interactive Data
06/16/2023 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
06/15/2023 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
06/12/2023 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
06/12/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/09/2023 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
06/09/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/08/2023 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
06/08/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/08/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/07/2023 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
06/06/2023 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
06/05/2023 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
06/02/2023 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
06/01/2023 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
05/31/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/31/2023 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
05/31/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/30/2023 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
05/25/2023 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
05/25/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/25/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/24/2023 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
05/24/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology 2023 Annual Meeting – Preclinical data in ASD model demonstrate prosocial effects of MM-402 –"
05/24/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/18/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/17/2023 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder – Over 50% of patients dosed across 20 active clinical sites – – On Track for Topline Results in late 2023 –"
05/12/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy